Jim Cramer Put These 16 Stocks Under a Microscope

14. TransMedics Group, Inc. (NASDAQ:TMDX)

Number of Hedge Fund Holders: 29

Commenting on TransMedics Group, Inc. (NASDAQ:TMDX) during the episode, Cramer said:

“Yeah, this is transplant therapy and… I think that it’s an interesting company. I’m not going to necessarily recommend it right here. It’s very expensive, but it is an interesting company.”

TransMedics Group (NASDAQ:TMDX) is a medical technology company that revolutionizes organ transplant treatment through its Organ Care System, which maintains and monitors donor organs outside the body, in addition to providing logistics and organ retrieval services. Carillon Tower Advisers stated the following regarding TransMedics Group, Inc. (NASDAQ:TMDX) in its Q4 2024 investor letter:

“TransMedics Group, Inc. (NASDAQ:TMDX) focuses on the care, transport, and viability of donor organs using a fleet of aircraft and logistics center. Despite the high demand for viable donor organs, challenges remain in harvesting and preserving these organs efficiently. In the most recent quarter, Transmedics reported impressive revenue growth, but missed consensus expectations, attributing the shortfall to seasonality rather than to competition. Shortly before its investor day in December, Transmedics hired a new chief financial officer and lowered full-year guidance by several million dollars.”